VEGFA and metastatic colorectal cancer: Bevacizumab (B), a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF-A), has proven clinical efficacy when used in first- or second-line treatment in association with fluorouracil-based chemotherapy (CT) in metastatic colorectal cancer patients (mCRC)1–3.